Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0L6CN
|
|||
| Former ID |
DNC000976
|
|||
| Drug Name |
N-(phosphonacetyl)-L-aspartate
|
|||
| Synonyms |
Sparfosic acid; PALA; n-(phosphonacetyl)-l-aspartic acid; N-(Phosphonoacetyl)-L-aspartic acid; Sparfosic Acid [INN]; NSC-224131; UNII-78QVZ7RG8L; 51321-79-0; L-ASPARTIC ACID, N-(PHOSPHONOACETYL)-; N-Phosphonacetyl-L-aspartate; Phosphonacetyl-L-aspartic acid; Acidum sparfosicum [INN-Latin]; Acido sparfosico [INN-Spanish]; Acide sparfosique [INN-French]; N-(Phosphonoacetyl)-asparaginsaeure; N-(Phosphonacetyl)-L-Aspartate; 78QVZ7RG8L; (2S)-2-[(2-phosphonoacetyl)amino]butanedioic acid; Acido sparfosico; Acide sparfosique; Acidum; SPARFOSIC ACID
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Discovery agent [ICD-11: N.A.] | Investigative | [1], [2], [3], [4], [5], [6], [7] | |
| Structure |
 |
Download2D MOL |
||
| Formula |
C6H7NO8P-3
|
|||
| Canonical SMILES |
C(C(C(=O)[O-])NC(=O)CP(=O)(O)[O-])C(=O)[O-]
|
|||
| InChI |
1S/C6H10NO8P/c8-4(2-16(13,14)15)7-3(6(11)12)1-5(9)10/h3H,1-2H2,(H,7,8)(H,9,10)(H,11,12)(H2,13,14,15)/p-3/t3-/m0/s1
|
|||
| InChIKey |
ZZKNRXZVGOYGJT-VKHMYHEASA-K
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
611404, 819129, 822428, 826681, 836566, 838364, 7889703, 8007076, 8008619, 8017755, 8020744, 8023779, 8176356, 11447091, 12012651, 14749967, 14847837, 34705821, 46391689, 46392970, 49872093, 57312369, 80534437, 104333201, 123080580, 123092439, 127344026, 127344027, 127344028, 129977131, 134223916, 134340335, 135001433, 136380866, 137116317, 165248681, 165248684, 165248687, 165248691, 165248696, 170485208, 177748648, 198944857, 226441525, 252422006
|
|||
| SuperDrug ATC ID |
M05BA07
|
|||
| SuperDrug CAS ID |
cas=105462246
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6. | |||
| REF 2 | Mechanism of resistance of variants of the Lewis lung carcinoma to N-(phosphonacetyl)-L-aspartic acid. Cancer Res. 1981 Mar;41(3):894-904. | |||
| REF 3 | Analogs of L-aspartic acid in chemotherapy for cancer. Cancer Treat Rep. 1979 Jun;63(6):1095-108. | |||
| REF 4 | Aspartate carbamoyltransferase activity, drug concentrations, and pyrimidine nucleotides in tissue from patients treated with N-(phosphonacetyl)-L-aspartate. Biochem Pharmacol. 1982 Oct 15;31(20):3317-21. | |||
| REF 5 | Long-term association of N-(phosphonacetyl)-L-aspartate with bone. Cancer Res. 1981 Jan;41(1):150-6. | |||
| REF 6 | Penetration of N-(phosphonacetyl)-L-aspartate into human central nervous system and intracerebral tumor. Cancer Res. 1980 Sep;40(9):3163-6. | |||
| REF 7 | Carbonic anhydrase inhibitors. Interaction of isozymes I, II, IV, V, and IX with organic phosphates and phosphonates. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1683-6. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.